Guiyang Xintian Pharmaceutical Co.,Ltd. (002873.SZ)
CNY 9.83
(0.1%)
CNY 9.83
(0.1%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 798.46 Million CNY | 11.73% |
| 2022 | 714.64 Million CNY | 12.72% |
| 2021 | 633.98 Million CNY | -10.41% |
| 2020 | 707.63 Million CNY | 88.76% |
| 2019 | 374.88 Million CNY | 15.81% |
| 2018 | 323.72 Million CNY | 38.17% |
| 2017 | 234.29 Million CNY | -13.33% |
| 2016 | 270.33 Million CNY | -0.99% |
| 2015 | 273.04 Million CNY | -1.52% |
| 2014 | 277.25 Million CNY | 24.69% |
| 2013 | 222.36 Million CNY | 40.38% |
| 2012 | 158.39 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 916.83 Million CNY | 5.97% |
| 2024 Q2 | 865.14 Million CNY | -2.48% |
| 2024 Q1 | 887.1 Million CNY | 11.1% |
| 2023 Q3 | 876.66 Million CNY | 5.51% |
| 2023 Q4 | 798.46 Million CNY | -8.92% |
| 2023 FY | 798.46 Million CNY | 11.73% |
| 2023 Q1 | 747.02 Million CNY | 4.53% |
| 2023 Q2 | 830.87 Million CNY | 11.22% |
| 2022 Q3 | 634.03 Million CNY | -4.87% |
| 2022 Q2 | 666.49 Million CNY | 3.41% |
| 2022 Q1 | 644.54 Million CNY | 1.67% |
| 2022 FY | 714.64 Million CNY | 12.72% |
| 2022 Q4 | 714.64 Million CNY | 12.72% |
| 2021 FY | 633.98 Million CNY | -10.41% |
| 2021 Q4 | 633.98 Million CNY | -4.02% |
| 2021 Q2 | 687.85 Million CNY | 0.12% |
| 2021 Q1 | 687.02 Million CNY | -2.91% |
| 2021 Q3 | 660.54 Million CNY | -3.97% |
| 2020 Q4 | 707.63 Million CNY | 13.66% |
| 2020 FY | 707.63 Million CNY | 88.76% |
| 2020 Q1 | 509.03 Million CNY | 35.78% |
| 2020 Q2 | 600.39 Million CNY | 17.95% |
| 2020 Q3 | 622.59 Million CNY | 3.7% |
| 2019 Q2 | 330.98 Million CNY | 7.19% |
| 2019 FY | 374.88 Million CNY | 15.81% |
| 2019 Q4 | 374.88 Million CNY | -9.02% |
| 2019 Q3 | 412.06 Million CNY | 24.5% |
| 2019 Q1 | 308.76 Million CNY | -4.62% |
| 2018 Q1 | 275.05 Million CNY | 17.4% |
| 2018 Q2 | 288.14 Million CNY | 4.76% |
| 2018 FY | 323.72 Million CNY | 38.17% |
| 2018 Q3 | 319.09 Million CNY | 10.74% |
| 2018 Q4 | 323.72 Million CNY | 1.45% |
| 2017 Q4 | 234.29 Million CNY | -22.14% |
| 2017 FY | 234.29 Million CNY | -13.33% |
| 2017 Q1 | 250.51 Million CNY | -7.33% |
| 2017 Q2 | 275.81 Million CNY | 10.1% |
| 2017 Q3 | 300.93 Million CNY | 9.11% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 Q4 | 270.33 Million CNY | 0.0% |
| 2016 FY | 270.33 Million CNY | -0.99% |
| 2016 Q2 | 268.52 Million CNY | 0.0% |
| 2015 Q3 | 273.04 Million CNY | 4.93% |
| 2015 Q4 | 273.04 Million CNY | 0.0% |
| 2015 Q2 | 260.21 Million CNY | 0.0% |
| 2015 Q1 | 260.21 Million CNY | -6.15% |
| 2015 FY | 273.04 Million CNY | -1.52% |
| 2014 FY | 277.25 Million CNY | 24.69% |
| 2014 Q4 | 277.25 Million CNY | 0.0% |
| 2014 Q3 | 277.25 Million CNY | 0.0% |
| 2014 Q1 | - CNY | 0.0% |
| 2013 FY | 222.36 Million CNY | 40.38% |
| 2012 FY | 158.39 Million CNY | 0.0% |